Acute myeloid leukemia screening

Revision as of 13:03, 11 April 2019 by Natalie Harpenau (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Acute myeloid leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute myeloid leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardigram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute myeloid leukemia screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute myeloid leukemia screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute myeloid leukemia screening

CDC on Acute myeloid leukemia screening

Acute myeloid leukemia screening in the news

Blogs on Acute myeloid leukemia screening

Directions to Hospitals Treating Acute myeloid leukemia

Risk calculators and risk factors for Acute myeloid leukemia screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

There are currently no guidelines for screening for acute myeloid leukemia. Monitoring of the complete blood count is done routinely.

Screening

There are currently no guidelines for screening for acute myeloid leukemia. Routine monitoring of complete blood count (CBC) once yearly is sufficient for screening for hematologic diseases in general.[1]


References

  1. Rumi E, Cazzola M (2017). "Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms". Blood. 129 (6): 680–692. doi:10.1182/blood-2016-10-695957. PMC 5335805. PMID 28028026.

Template:WH Template:WS